Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399428 | 1.00 | ALDH1A1 (0.33) | ALDH1A1PDE4DHRH3CNR2L3MBTL1 | |
| SCHEMBL6399810 | 0.83 | ALDH1A1 (0.34) | ALDH1A1LMNA | |
| SCHEMBL6399811 | 0.83 | ALDH1A1 (0.34) | ALDH1A1LMNA | |
| SCHEMBL6398449 | 0.74 | CYP46A1 (0.37) | ALDH1A1PDE4DHRH3MEN1HPGD | |
| SCHEMBL28444367 | 0.73 | L3MBTL1 (0.45) | ALDH1A1HRH3L3MBTL1LMNATAAR1 | |
| SCHEMBL6397918 | 0.71 | NPC1 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL6544010 | 0.70 | HRH3 (0.41) | ALDH1A1HRH3L3MBTL1LMNATAAR1 | |
| SCHEMBL6544004 | 0.70 | HRH3 (0.41) | ALDH1A1HRH3L3MBTL1LMNATAAR1 | |
| SCHEMBL329010 | 0.67 | TRIM24 (0.32) | ALDH1A1PDE4D | |
| SCHEMBL10361551 | 0.67 | SYK (0.43) | ALDH1A1HRH3SYKLMNATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949585-B2 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375465-A9 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375479-A1 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | CCR1, CCL2, CCR5 | ALDH1A1 4117/4885PDE4D 2759/4885HRH3 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.